The Paper's reporter Li Xiaoxiao
Yunnan Baiyao lost 1.5 billion yuan to speculate on the hot search.
On the evening of October 27, Yunnan Baiyao Group Co., Ltd. (Yunnan Baiyao, 000538) disclosed the third quarterly report, the company's operating income in the first three quarters was 28.363 billion yuan, an increase of 18.52% year-on-year, the net profit attributable to the mother was 2.451 billion yuan, down 42.38% year-on-year, and the non-net profit was 2.931 billion yuan, down 7.96% year-on-year; in a single quarter, the operating income in the third quarter was 9.279 billion yuan, an increase of 9.98% year-on-year. Net profit attributable to the mother was 649 million yuan, down 63.94% year-on-year, and deducted non-net profit of 1.046 billion yuan, down 21.70% year-on-year.
With double-digit revenue growth, why has Yunnan Baiyao's net profit been declining? This has something to do with its stock investments.
Judging from the changes in the main accounting data and financial indicators published, during the reporting period, the fair value change profit and loss of Yunnan Baiyao's trading financial assets during the holding period was -1.555 billion yuan. Yunnan Baiyao stressed in the financial report that the company recognized the share payment fee of 866 million yuan in the current period, but did not in the previous period, excluding the impact of this part of the expense, the company achieved a non-net profit attributable to the shareholders of the listed company of 3.667 billion yuan, an increase of 15.14% year-on-year.
"Stock speculation lost 1.5 billion yuan" made Yunnan Baiyao questionable, and some netizens believed that "not doing the right thing" and "harvesting the money earned by leeks, they went to be leeks again". On the investor interaction platform, some investors directly asked: "Is it because your company's future development strategy is weak?" In its interaction with investors, Yunnan Baiyao stressed that its main business remained stable.
On October 28, the staff of Yunnan Baiyao Securities Department said in a response to the surging news reporter on the phone that in fact, the company has responded to the interactive platform, including the company's investor exchanges and related documents, and it is indeed gradually compressed, will not increase securities investment, and will definitely focus on the main business.
Whose shares did Yunnan Baiyao buy?
The third quarterly report did not disclose detailed trading financial assets, and from the 2021 semi-annual report, its financial asset investment includes Xiaomi Group, Yili Shares, E Fangda Yufeng Return Bonds, Fuguo Dingli Pure Bond Bonds, Tencent Holdings, Fuguo Xiangli One-Year, Guangfa Juli Bonds Class A, Hengrui Pharmaceutical, Tongwei Shares, China Antibodies, etc., involving domestic and foreign stocks, funds and other securities.
According to the data disclosed in the semi-annual report, at that time, Xiaomi Group, Yili Shares, Hengrui Pharmaceutical, Neutral Antibody and other reporting periods were all loss-making, of which the loss of investment in Xiaomi Group reached up to 610 million yuan, and the loss of investment in Hengrui Pharmaceutical was 180 million yuan.
Yunnan Baiyao semi-annual report on trading financial assets part of the data
According to the 2021 semi-annual report, Yunnan Baiyao was created in 1902, is a chinese time-honored brand, in 1993 as the first listed company in Yunnan listed on the Shenzhen Stock Exchange, in 1996 to achieve the complete unification of the brand, in 1999 successfully implemented enterprise reengineering, in 2005 launched the "stable central, sudden two wings" product strategy, in 2010 began to implement the "new white medicine, big health" industrial strategy.
Yunnan Baiyao was once known as "a brother in traditional Chinese medicine", but now its market value has been surpassed by Katazai. Or affected by the above news, on October 28, Yunnan Baiyao opened sharply low, the intraday minimum to 84 yuan, as of the close, reported 88.36 yuan, down 3.83%, the market value of 113.33 billion yuan.
40 pharmaceutical and biological listed companies have a net gain on fair value changes
It is not uncommon for listed companies to participate in investments such as stocks, and the listed pharmaceutical companies that drag down the overall performance are not Yunnan Baiyao. According to wind data, as of October 28, a total of 40 listed pharmaceutical companies had a net gain on fair value changes in the state of loss, ranging from 10,000 to 1.5 billion.
As of October 28, the net income from the fair value change of listed pharmaceutical and biological companies was a loss-making number of companies
Judging from the above list, there are many giants in hengrui medicine, aier ophthalmology, Kanglong Huacheng and other subdivisions, specifically, Yunnan Baiyao has the most losses, followed by Hainan Haiyao, with a loss of 260 million yuan. According to Hainan Haipharm's previous three quarterly reports, this part of the loss was mainly due to the recognition of fair value changes in stocks such as China Antibody Pharmaceutical Co., Ltd. in the reporting period. It is worth noting that the investment content of Yunnan Baiyao also includes the company of China Antibody.
Shanghai Laoshi, one of the four major blood product giants, also had a net gain on fair value changes in the third quarter, which was 36.36 million. Looking back at history, Shanghai Laoshi has suffered investment losses before. The company began venture capital matters as early as 2015, and the 2018 annual report showed that the net profit attributable to the owners of the parent company was a loss of 1.518 billion yuan, a year-on-year decrease of 281.66%, of which the investment profit and loss on the disposal of financial assets measured at fair value and the change of which was included in the profit and loss of the current period was a loss of 1.14 billion yuan. At that time, Shanghai Laoshi also received an inquiry letter for this reason.
Recently, Haoyue Nursing (605009), whose main business is personal hygiene products, also recently received an inquiry letter due to investment losses. On the evening of October 12, Haoyue Nursing announced that its subsidiary Jiangsu Haoyue invested a cumulative amount of 153 million yuan in futures accounts, and as of October 11, the futures account had accumulated losses (including floating losses) of 69.3415 million yuan.
For the follow-up of investment losses, most of the follow-up decisions of enterprises are opting out.
Shanghai Laoshi stressed in the reply letter at that time that in view of the current domestic and foreign economic environment and securities market conditions, in line with the principle of rational investment and prudent decision-making, according to the company's internal control system and the requirements of relevant regulations, the company will no longer participate in new securities investment, the original securities investment will also be gradually withdrawn at an appropriate time in the future, and will no longer carry out securities investment in the future, and the company's strategy and development will fully focus on the main business of blood products and the deep cultivation and refinement of biological products-related industries.
On October 25, Haoyue Nursing responded to the investment loss in the reply letter, saying that the company decided to terminate the futures investment in an orderly manner, choose the opportunity to reduce and close the position of the current position, terminate the futures business as soon as possible, cancel the futures account, and the company will still invest its main energy in the main business operation in the future. The company will follow up with a diligent and responsible attitude towards investors, prudent decision-making, minimize the loss of futures investment, and fulfill the information disclosure obligation in accordance with the regulations.
Editor-in-Charge: It's Winter